Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, ...

The Muscular Dystrophy Association (MDA) celebrates today's announcement that the U.S. Food and Drug Administration (FDA) has approved a High Dose Regimen of SPINRAZA(R) (nusinersen) for the treatment ...

Wall Street surged Tuesday as speculation of a de-escalation in the Middle East conflict eased oil price and inflation fears.

Biogen will buy Apellis Pharmaceuticals for about $5.6 billion, adding a promising kidney disease drug to broaden its ...

In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will ...

March 30 (Reuters) - The U.S. Food and Drug Administration has approved a higher-dose version of Biogen's drug for a rare ...

In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help ...

Eli Lilly agrees to acquire sleep disorder drug developer Centessa Pharmaceuticals for approximately $7.8 billion, while ...

After a surprise rejection in September last year, the FDA has signed off on a high-dose formulation of Biogen’s spinal muscular atrophy drug Spinraza. The approval, announced Monday, will allow a ...

Biogen, Inc. to acquire WWH portfolio company, Apellis Pharmaceuticals, Inc. The Company notes the announcement on Tuesday, 31 March 2026 that Biogen Inc. ("Biogen") has entered into an agreement to ...

Biogen, Inc. to acquire BIOG portfolio company, Apellis Pharmaceuticals, Inc. The Company notes the announcement on Tuesday, 31 March 2026 that Biogen Inc. ("Biogen") has entered into an agreement to ...

The most common side effects of SPINRAZA in the Low Dose Regimen in infantile- and later- onset SMA include lower respiratory infection, constipation, fever, headache, vomiting, back pain, and ...